List of investigational other psychiatric disorder drugs

This is a list of investigational other psychiatric disorder drugs, or drugs that are currently under development for clinical use for the treatment of other or unspecified psychiatric disorders but are not yet approved. Some examples of such conditions include adjustment disorders, behavioral disorders, behavioral addictions like gambling addiction, impulse–control disorders, other personality disorders, and somatoform disorders.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]".

This list was last comprehensively updated in January 2026. It is likely to become outdated with time.

Under development

Phase 3

• Lumateperone (Caplyta; ITI-007; ITI-722) – non-selective monoamine receptor modulator – behavioral disorders https://adisinsight.springer.com/drugs/800026498
• Lurasidone (DSP-1349M; Latuda; SM-13496; SMP-13496) – atypical antipsychotic (non-selective monoamine receptor modulator) – psychiatric disorders https://adisinsight.springer.com/drugs/800007206
• Ralmitaront (NTX-2001; RG-7906; RO-6889450) – trace amine-associated receptor 1 (TAAR1) agonist – psychiatric disorders https://adisinsight.springer.com/drugs/800044887
• Venlafaxine extended-release (ALM-002; ALM002) – undefined mechanism of action – mental disorders https://adisinsight.springer.com/drugs/800065734 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215429Orig1s000,215429Orig2s000AdminCorres.pdf

Phase 2/3

• Evenamide (NW-3509; NW-3509A) – sodium channel blocker – psychiatric disorders https://adisinsight.springer.com/drugs/800026870
• Psilocybin (CYB001; CYB-001; INT0052/2020) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – mental disorders https://adisinsight.springer.com/drugs/800059460

Phase 2

• ALM-007 (ALM007) – undefined mechanism of action – psychiatric disorders https://adisinsight.springer.com/drugs/800069382 https://synapse.patsnap.com/drug/500fc5460c4c40e7811b86485bb37477
• Deudextromethorphan (AVP-786; CTP-786; d-DM; deuterated-DM; deuDXM; deu-DXM; deuterated DXM) – NMDA receptor antagonist, sigma receptor agonist, other actions – impulse–control disorders https://adisinsight.springer.com/drugs/800035704
• Fasedienol (Aloradine; AM-005; PH-94B; PH94B) – vomeropherine (chemoreceptor cell modulator) – adjustment disorders https://adisinsight.springer.com/drugs/800014893
• Psilocybin (COMP360; COMP-360) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – somatoform disorders https://adisinsight.springer.com/drugs/800050861
• Psilocybin (PEX-010) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – adjustment disorders https://adisinsight.springer.com/drugs/800072170
• SRX-246 (SRX246; API-246) – vasopressin V_1A receptor antagonist – impulse–control disorders https://adisinsight.springer.com/drugs/800023656
• SXC-2023 – cystine–glutamate antiporter (SLC7A11; System x_c- or Sxc) activator – impulse–control disorders https://adisinsight.springer.com/drugs/800050452 https://synapse.patsnap.com/drug/f23045c896ea40f08e01e1e3e5ef6615

Phase 1/2

• SRX-246 (SRX246; API-246) – vasopressin V_1A receptor antagonist – behavioral disorders https://adisinsight.springer.com/drugs/800023656

Phase 1

• 5-MeO-MiPT (MSD-001; MS001; MSD-101; MSD-201; MSD-X01) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – mental disorders https://adisinsight.springer.com/drugs/800080520
• CVN-766 (CVN766) – orexin OX₁ receptor antagonist – psychiatric disorders https://adisinsight.springer.com/drugs/800066143
• "Glutamate receptor modulator" - Boehringer Ingelheim – glutamate receptor modulator – mental disorders https://adisinsight.springer.com/drugs/800082130
• KNX-100 (KNX100; SOC-1) – oxytocin-like drug / indirect oxytocin receptor modulator – behavioral disorders https://adisinsight.springer.com/drugs/800056121
• MSP-2020 (MSP2020) – serotonin 5-HT_2A receptor agonist – mental disorders https://adisinsight.springer.com/drugs/800070476 https://synapse.patsnap.com/drug/37179bf1df5742e4ace1bde7768dd4ca
• NBI-1140675 – vesicular monoamine transporter 2 (VMAT2) inhibitor – psychiatric disorders https://adisinsight.springer.com/drugs/800081696
• Radiprodil (RGH-896) – ionotropic glutamate NR2B-containing NMDA receptor antagonist – behavioral disorders https://adisinsight.springer.com/drugs/800069843
• "Receptor agonist" - Boehringer Ingelheim – undefined mechanism of action – mental disorders https://adisinsight.springer.com/drugs/800082131
• SYT-510 (SYT510) – endocannabinoid reuptake inhibitor – psychiatric disorders https://adisinsight.springer.com/drugs/800061198

Clinical phase unknown

• Eplivanserin/volinanserin – fixed-dose combination of eplivanserin (serotonin 5-HT_2A receptor antagonist) and volinanserin (serotonin 5-HT_2A receptor antagonist) – psychiatric disorders https://adisinsight.springer.com/drugs/800076570 https://www.labiotech.eu/podcast/terran-biosciences-reformulating-psychedelics/

Preclinical

• Aripiprazole controlled release (LYN-006; ultra long-acting aripiprazole) – atypical antipsychotic (non-selective monoamine receptor modulator) – psychiatric disorders https://adisinsight.springer.com/drugs/800070633
• CYB-210010 (CYB210010; 2C-T-TFM; 2C-T-36) – serotonin 5-HT₂ receptor agonist and serotonergic psychedelic – psychiatric disorders https://adisinsight.springer.com/drugs/800078162
• Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α₂-adrenergic receptor agonist – psychiatric disorders https://adisinsight.springer.com/drugs/800050611
• DT-201 (DT201) – α₅ subunit-containing GABA_A receptor negative allosteric modulator – psychiatric disorders https://adisinsight.springer.com/drugs/800083618
• KAR-501 (KAR501) – undefined mechanism of action – mental disorders https://adisinsight.springer.com/drugs/800059739
• Lu AG06474 (Lu-AG-06474) – monoacylglycerol lipase (MAGL) inhibitor – psychiatric disorders https://adisinsight.springer.com/drugs/800064963
• Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABA_A receptor positive allosteric modulator) – gambling https://adisinsight.springer.com/drugs/800029334
• NBI-1065890 (NBI-890) – vesicular monoamine transporter 2 (VMAT2) inhibitor – psychiatric disorders https://adisinsight.springer.com/drugs/800076420
• ORX-489 (ORX489) – orexin OX₂ receptor antagonist – psychiatric disorders https://adisinsight.springer.com/drugs/800080461
• OV-350 (AZ-8333) – potassium–chloride-cotransporter agonist – psychiatric disorders https://adisinsight.springer.com/drugs/800066678
• TPT-0301 (neuropathic pain therapeutic) – cannabinoid receptor modulator – mental disorders https://adisinsight.springer.com/drugs/800072248

Research

• OWP-107 (OWP107) – undefined mechanism of action – psychiatric disorders https://adisinsight.springer.com/drugs/800072036
• Psilocybin (REL-P11) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – psychiatric disorders https://adisinsight.springer.com/drugs/800066198
• Research programme: mental disorder therapies - Mindstate Design Labs (MSD-X02) – undefined mechanism of action – mental disorders https://adisinsight.springer.com/drugs/800083624

Not under development

No development reported

• 4-Chlorokynurenine (4-CL-KYN; 7-CL-KYNA; AV-101; L-4-chlorokynurenine; L-4-CL-KYN) – NMDA receptor antagonist, kynurenine modulator – psychiatric disorders https://adisinsight.springer.com/drugs/800019948
• Acetaminophen/naltrexone (paracetamol/naltrexone; ALLOD-2; ALLOD-2H; ATNC-05) – combination of acetaminophen (analgesic) and naltrexone (opioid receptor antagonist/immunomodulator) – adjustment disorders https://adisinsight.springer.com/drugs/800038509
• Deudextromethorphan (AVP-786; CTP-786; d-DM; deuterated-DM; deuDXM; deu-DXM; deuterated DXM) – NMDA receptor antagonist, sigma receptor agonist, other actions – psychiatric disorders https://adisinsight.springer.com/drugs/800035704
• Deulumateperone (ITI-1284; ITI-1284 ODT-SL) – non-selective monoamine receptor modulator – behavioral disorders https://adisinsight.springer.com/drugs/800062544
• Ecopipam (EBS-101; PSYRX-101; SCH-39166) – dopamine D₁ receptor antagonist – gambling https://adisinsight.springer.com/drugs/800000645
• Ketamine (AWKN-001; AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist, dissociative hallucinogen – gambling, impulse–control disorders https://adisinsight.springer.com/drugs/800069916
• LB-100 (LB100; LB-1) – protein phosphatase 2A (PP2A) inhibitor – behavioral disorders https://adisinsight.springer.com/drugs/800037966
• Lu-AF95245 – potassium channel agonist – mental disorders https://adisinsight.springer.com/drugs/800056896
• Midomafetamine (MDMA; ecstasy; MDMA-CUREfilm) – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT₂ receptor agonist, entactogen – mental disorders https://adisinsight.springer.com/drugs/800063002
• Olanzapine (BR-5402; LY-170053; LY-170052; Midax; Zypadhera; Zyprexa) – atypical antipsychotic (non-selective monoamine receptor modulator) – personality disorders https://adisinsight.springer.com/drugs/800001477
• OMS-527 (OMS527; OMS-182399) – phosphodiesterase PDE7 inhibitor – impulse–control disorders https://adisinsight.springer.com/drugs/800028937
• Opipramol (Ensidon; G-33040; Insidon; Nisidana; OPIprol) – sigma receptor agonist, atypical tricyclic antidepressant (TCA) – somatoform disorders https://adisinsight.springer.com/drugs/800002007
• Pimavanserin (ACP-103; BVF-048; Nuplazid) – serotonin 5-HT_2A receptor antagonist – psychiatric disorders https://adisinsight.springer.com/drugs/800014997
• Pirepemat (IRL-752) – various actions – behavioral disorders https://adisinsight.springer.com/drugs/800044794
• PT-00114 (PT00114) – corticotropin-releasing hormone (CRH) inhibitor – impulse–control disorders https://adisinsight.springer.com/drugs/800049398
• Research programme: behavioural disorder therapeutics - Evotec SE/Neumora Therapeutics – undefined mechanism of action – behavioral disorders https://adisinsight.springer.com/drugs/800050093
• Research programme: GPR151 modulating therapeutics - Omeros Corporation – GPR151 modulators – mental disorders https://adisinsight.springer.com/drugs/800060211
• Research programme: neuropsychiatric disorder therapies - Roche/PsychoGenics – undefined mechanism of action – psychiatric disorders https://adisinsight.springer.com/drugs/800028373
• Research programme: small molecule therapeutics - Evotec/Pasithea Therapeutics – undefined mechanism of action – mental disorders https://adisinsight.springer.com/drugs/800065854
• Risperidone (QR-106) – atypical antipsychotic (non-selective monoamine receptor modulator) – psychiatric disorders https://adisinsight.springer.com/drugs/800049995
• SKL-15508 (SKL-A4R; SKL15508) – α₇ subunit-containing nicotinic acetylcholine receptor partial agonist – mental disorders https://adisinsight.springer.com/drugs/800041304

Suspended

• BIA-102474 (BIA-10; BIA 10–2474) – fatty acid amide hydrolase (FAAH) inhibitor – psychiatric disorders https://adisinsight.springer.com/drugs/800044029

Discontinued

• ADX-71149 (ADX71149; JNJ-1813; JNJ-40411813; JNJ-mGluR2-PAM) – metabotropic glutamate mGlu₂ receptor positive allosteric modulator – psychiatric disorders https://adisinsight.springer.com/drugs/800030424
• ALTO-203 (ALTO203) – histamine H₃ receptor antagonist – psychiatric disorders https://adisinsight.springer.com/drugs/800071570
• CORT-108297 (ADS-108297) – glucocorticoid receptor antagonist – psychiatric disorders https://adisinsight.springer.com/drugs/800028115
• CYB-003 (CYB003; HLP-003; HLP003; deuterated psilocin) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – psychiatric disorders https://adisinsight.springer.com/drugs/800062409
• CYB-004 (CYB004; HLP-004; HLP004; deuterated dimethyltryptamine; deuterated DMT; dDMT) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, serotonergic psychedelic – psychiatric disorders https://adisinsight.springer.com/drugs/800062410
• Davalintide (AC-2307; second-generation amylinomimetic) – amylin receptor agonist – psychiatric disorders https://adisinsight.springer.com/drugs/800025197
• Nalmefene oral (CPH-101; JF-1; Lu AA36143; nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – gambling https://adisinsight.springer.com/drugs/800000302
• Pimavanserin (ACP-103; BVF-048; Nuplazid) – serotonin 5-HT_2A receptor antagonist – behavioral disorders https://adisinsight.springer.com/drugs/800014997
• Quetiapine (FK-949; FK949E; ICI-204636; Seroquel) – non-selective monoamine receptor modulator – behavioral disorders https://adisinsight.springer.com/drugs/800001768
• TAK-137 (TAK137) – AMPA receptor positive allosteric modulator – psychiatric disorders https://adisinsight.springer.com/drugs/800039145
• Tasipimidine (ODM-105) – α_2A-adrenergic receptor modulators – psychiatric disorders https://adisinsight.springer.com/drugs/800070674
• TMP-301 (TMP301; Heptares 25; HTL-0014242; HTL14242) – metabotropic glutamate mGlu₅ receptor antagonist – psychiatric disorders https://adisinsight.springer.com/drugs/800053572

Clinically used drugs

Market withdrawal

• Mesocarb (armesocarb; MLR-1019) – atypical dopamine reuptake inhibitor (DRI) – psychiatric disorders https://adisinsight.springer.com/drugs/800034792

See also

• Lists of investigational drugs

References

External links

• AdisInsight - Springer